Arcturus Therapeutics ARCT 深 沪
已收盘 10-03 16:00:00 美东时间
22.56
+0.680
+3.11%
华盛通- 最 高23.595
- 今 开21.97
- 成交量 168.40万股
- 最 低 20.08
- 昨 收 21.88
- 总市值 6.13亿
- 52周最高 23.595
- 市盈率 静 --
- 换手率 6.20%
- 52周最低 8.04
- 委 比 78.99%
- 总股本 2715.45万
- 历史最高 129.71
- 量 比 1.76
- 振 幅 16.06%
- 历史最低 4.11
- 每 手 1
- 风险率 3.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
09-30 01:35
Arcturus Therapeutics Partners on New COVID-19 Vaccine Launch
Arcturus Therapeutics ( ($ARCT) ) has issued an announcement. On September 26, ...
09-26 18:29
Cathie Wood Dumps $5.2 Million Worth of This AI Stock, Here's What Ark Bought Instead
Ark Invest decided to sell shares of Tempus AI (TEM), despite positive news of FDA clearance for its diagnostic device. They also made other key trades.
09-24 09:17
为了让始祖鸟当网红，安踏把灵魂丢了
来源：源媒汇 作者 | 王言 在被全网捧成“网红”后，始祖鸟还是迎来了营销的反噬。 9月19日，艺术家蔡国强与户外品牌始祖鸟联手，在西藏喜马拉雅山脉江孜...
09-22 17:27
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
Arcutis announced new data on ZORYVE's efficacy for seborrheic dermatitis, atopic dermatitis, and psoriasis across diverse skin types and age groups, showing improved symptoms and quality of life with good tolerability.
09-17 08:00
ARCT, TEM: Cathie Wood Expands Bet in Biotech, Trims Stake in Tempus AI Stock
Popular investorCathie Wood’s ARK Investmade key portfolio moves on...
09-16 11:59
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
Arcutis Biotherapeutics announced the submission of a supplemental New Drug Application (sNDA) to the FDA for ZORYVE cream 0.3% to treat plaque psoriasis in children as young as 2 years old. If approved, ZORYVE would be the first and only topical PDE4 inhibitor for this age group, offering a steroid-free option for sensitive areas like the face and intertriginous regions. The submission is supported by a 4-week MUSE study and long-term safety dat...
09-03 15:43
Arcturus Therapeutics’ COVID-19 Vaccine Approved in Japan
Arcturus Therapeutics ( ($ARCT) ) has issued an update. On August 29, 2025, Mei...
08-29 18:27
